PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31350270-9	2019	Changes from baseline in DAS28-C-reactive protein/erythrocyte sedimentation rate and the ACR core set were significantly greater for both peficitinib doses versus placebo at week 12/ET (p<0.001).	peficitinib	138-149	C-reactive protein	Homo sapiens	31-49	
33929089-1	2021	The aim was to analyze the relationship between peficitinib exposure and efficacy response according to American College of Rheumatology (ACR) 20 criteria and 28-joint disease activity score based on C-reactive protein (DAS28-CRP) in rheumatoid arthritis (RA) patients, and to identify relevant covariates by developing exposure-response models.	peficitinib	48-59	C-reactive protein	Homo sapiens	226-229	
33929089-6	2021	The exposure-response models of effect of peficitinib on duration-dependent increase in ACR20 response rate and decrease in DAS28-CRP were adequately described by a continuous time Markov model and an indirect response model, respectively, with a sigmoidal Emax saturable of drug exposure in RA patients.	peficitinib	42-53	C-reactive protein	Homo sapiens	130-133	
33929089-9	2021	Our exposure-response models of peficitinib in RA patients satisfactorily described duration-dependent improvements in ACR20 response rates and DAS28-CRP measurements, and provided consistent covariate effects.	peficitinib	32-43	C-reactive protein	Homo sapiens	150-153	
27748083-5	2017	Significant decreases from baseline in the Disease Activity Score in 28 joints using the C-reactive protein level were seen in the peficitinib 50 mg (P &lt; 0.05) and 150 mg (P &lt; 0.01) groups compared with placebo at week 12.	peficitinib	131-142	C-reactive protein	Homo sapiens	89-107	
35267027-9	2022	Higher baseline CRP and/or prednisolone dose were associated with reduced peficitinib efficacy.	peficitinib	74-85	C-reactive protein	Homo sapiens	16-19